Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Europese focus op geïndividualiseerde behandeling van endometriumcarcinoom
jul 2019 | Gynaecologische oncologie